Docket #: S23-309

Development of theragnostic radiopharmaceuticals for pancreatic cancer

Stanford researchers at the Ferrara Lab have developed a method to select receptor targets for molecular imaging and therapies by applying spatial transcriptomics, proteomics, and machine learning. This method has been used to identify Claudin-4 as a target for pancreatic ductal adenocarcinoma (PDAC), as well as peptides to this target to demonstrate molecular imaging. This approach can also be applied to the design of molecular imaging strategies to develop radiotheragnostics across a range of disease targets.

Stage of Development

- *In vivo* studies
- Demonstrated the identified peptides using molecular imaging

Applications

- Pancreatic cancer radiotheragnostics development

Advantages

- New method to develop pancreatic cancer radiotheragnostics
- Broad strategy that can be applied to other cancers

Patents

- Published Application: WO2025076450

Innovators

- Katherine Ferrara
- Jai Woong Seo
- James Wang

Licensing Contact

Eileen Lee

Email